GSK1614235

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Diabetes Mellitus, Type 2

Phase 1

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

CompletedNCT00976261

GlaxoSmithKlineDiabetes Mellitus, Type 2

Start: 2009-10-17End: 2010-09-05Updated: 2017-06-08

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.

CompletedNCT01607385

GlaxoSmithKlineDiabetes Mellitus, Type 2

Start: 2012-05-18End: 2012-12-03Updated: 2017-07-26

Related Papers

Analysis of <scp>C4</scp> Concentrations to Predict Impact of Patient‐Reported Diarrhea Associated With the Ileal Bile Acid Transporter Inhibitor Linerixibat

CPT Pharmacometrics & Systems Pharmacology2025-02-132 citations